New Roche Esbriet data show clinical benefits of continued and long-term treatment in patients with idiopathic pulmonary fibrosis (IPF), according to research presented at ERS 2015.
A pooled analysis from three phase III studies – ASCEND and CAPACITY I and II – show a 38% reduction in risk of death after up to two years on Esbriet treatment.
These data are the first long-term results to show continued reduction in risk of death for IPF patients.
Additionally, an ad-hoc analysis of the pooled ASCEND and CAPACITY I and II studies show clinical benefits of continued Esbriet treatment after hospitalization.
- Disorders & Diseases
- Public Health
- Products & Treatment
- Department Management
- Edition Archive